Labs Asap LLC

Labs Asap LLC was paid $2.93M by Medicaid between Feb 2019 and Dec 2024, across 96 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 28% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Florida

Rank by total paid#22 of 225

Median peer was paid$74K

This provider vs. median40×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2019	2,069	$7K
2020	4,145	$183K
2021	41,302	$649K
2022	89,759	$1.05M
2023	59,933	$534K
2024incomplete	67,747	$506K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	28%	19,567	12,378	$820K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	15%	9,711	4,804	$444K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	6.8%	8,440	6,515	$200K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	4.9%	621	570	$142K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	2.3%	18,472	11,581	$68K
80323		2.1%	8,746	7,447	$62K
80346		2.0%	3,524	2,981	$58K
80334		1.9%	7,397	6,364	$54K
87631		1.8%	1,629	1,384	$51K
80377		1.7%	6,334	5,518	$50K
87481		1.7%	5,679	2,948	$50K
80343		1.4%	6,335	5,525	$41K

84 more codes

80321		1.3%	2,263	$39K
80320		1.2%	6,344	$35K
80361		1.1%	5,879	$31K
80372		1.1%	5,880	$31K
80364		1.0%	5,808	$31K
80354		1.0%	5,807	$31K
80348		1.0%	5,804	$31K
80356		1.0%	5,783	$31K
80368		1.0%	5,860	$30K
80358		1.0%	5,829	$30K
87640		1.0%	4,395	$30K
80370		1.0%	5,692	$30K
80349		<1%	5,640	$29K
80359		<1%	5,784	$28K
80353		<1%	5,783	$28K
83992		<1%	5,804	$27K
80325		<1%	4,402	$25K
87529		<1%	1,383	$22K
80345		<1%	5,724	$22K
87653		<1%	4,256	$18K
80351		<1%	3,380	$18K
87581		<1%	2,308	$16K
87486		<1%	2,300	$16K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	681	$15K
80347		<1%	2,209	$13K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	1,709	$13K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	<1%	7,308	$13K
80337		<1%	2,077	$13K
80365		<1%	2,214	$12K
80367		<1%	2,351	$12K
80373		<1%	2,342	$12K
80360		<1%	2,363	$12K
80366		<1%	2,198	$12K
87563		<1%	2,733	$12K
87541		<1%	1,417	$12K
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	<1%	1,907	$11K
80371		<1%	2,150	$11K
80352		<1%	2,003	$11K
80342		<1%	2,095	$10K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	1,365	$10K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	1,353	$10K
80326		<1%	1,283	$7K
87641		<1%	2,441	$6K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	<1%	90	$6K
80333		<1%	955	$6K
87500		<1%	1,865	$2K
81220	CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants	<1%	16	$2K
87086	Culture, bacterial; quantitative colony count, urine	<1%	1,775	$2K
87181		<1%	1,495	$2K
87511		<1%	381	$2K
87637	Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV	<1%	38	$855.78
81513		<1%	17	$600.93
86703		<1%	176	$410.73
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	<1%	67	$377.90
80074		<1%	31	$375.21
84443	Thyroid stimulating hormone (TSH)	<1%	117	$361.94
81001		<1%	736	$228.61
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	19	$220.08
83036	Hemoglobin; glycosylated (A1C)	<1%	87	$148.31
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	310	$130.04
80053	Comprehensive metabolic panel	<1%	239	$107.14
87186		<1%	100	$91.14
87081		<1%	31	$86.88
80061	Lipid panel	<1%	84	$46.38
86787		<1%	34	$42.50
82607		<1%	18	$36.46
86762		<1%	16	$29.75
86593		<1%	113	$27.07
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	160	$22.89
85660		<1%	35	$17.24
80332		<1%	83	$10.40
81002		<1%	44	$9.24
87340		<1%	15	$6.88
86850		<1%	15	$3.69
82950		<1%	15	$3.16
86592		<1%	27	$2.84
86900		<1%	15	$1.99
36415	Collection of venous blood by venipuncture	<1%	417	$1.41
80355		0%	1,959	$0.00
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	0%	12	$0.00
G2024	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source	0%	344	$0.00
80350		0%	81	$0.00
80335		0%	81	$0.00
80324		0%	80	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialENCIENZO, ARCELI (TECHNICAL SUPERVISOR/VP OPERATIONS)